secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0001104659-24-128491
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

BMS terminates collaboration with Century Therapeutics without cause; effective March 12, 2025
--------------------------------------------------------------------------------

- BMS notified Century on Dec 12, 2024 of termination of the 2022 Research, Collaboration and License Agreement.
- Termination covers all iPSC-derived NK and gamma delta T cell programs for hematologic malignancies.
- Century will evaluate opportunities in AML and multiple myeloma under ongoing strategic review of pre-clinical pipeline.
- Both parties will cooperate on termination provisions; no financial details of termination disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924128491/0001104659-24-128491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924128491/tm2431062d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-128491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer